<DOC>
	<DOCNO>NCT02256345</DOCNO>
	<brief_summary>This study perform determine safety , tolerability , dose-response inorganic nitrate exercise capacity HFpEF . There two primary goal study : 1 . Determine population-specific pharmacokinetics dose KNO3 safely give subject HFpEF . 2 . Determine dose-response effect nitrate supplementation exercise capacity , evidence peak oxygen consumption ( peak VO2 ) , physiologic adaptation exercise .</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodynamics , Impact Inorganic Nitrate Exercise HFpEF</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<criteria>1 . NYHA Class IIIII symptom . 2 . LV EF &gt; 50 % . 3 . Stable medical therapy least 1 month . 4 . Evidence significant diastolic dysfunction , meet European Society Echocardiography criterion HFpEF . Exclusion Criteria 1 . Any rhythm sinus native conduction . 2 . Inability exercise . 3 . Moderate great valvular disease . 4 . Hypertrophic , infiltrative , inflammatory cardiomyopathy . 5 . Pericardial disease . 6 . Current angina . 7 . Acute coronary syndrome coronary intervention within past 2 month . 8 . Primary pulmonary arteriopathy . 9 . Clinically significant lung disease . 10 . Ischemia stress test without subsequent revascularization . 11 . Treatment phosphodiesterase inhibitor withhold . 12 . Treatment organic nitrate allopurinol . 13 . Significant liver disease impact synthetic function volume control . 14 . Poor echocardiographic window . 15. eGFR &lt; 30 mL/min/m2 Cr &gt; 2.5 . 16 . Current smoking . 17 . Alcohol dependency . 18 . History Barret 's esophagus . 19 . G6PD deficiency 20 . Methemoglobinemia baseline methemoglobin level &gt; 3 % prior study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>